Muktiraj Mehta, MD
Psychiatry · Cassopolis, MINPI 1588658017
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 548 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Sunovion Pharmaceuticals Inc.$955
- Johnson & Johnson$867
- plus $3K from 14 others
What the payments were for
- Food & beverage$12,41999%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 128 | $2,931 |
| Alkermes, Inc. | 83 | $1,959 |
| Otsuka America Pharmaceutical, Inc. | 53 | $1,396 |
| Neurocrine Biosciences, Inc. | 40 | $1,141 |
| Sunovion Pharmaceuticals Inc. | 56 | $955 |
| Johnson & Johnson(2 entities) | 46 | $867 |
| AbbVie(2 entities) | 52 | $852 |
| Teva Pharmaceuticals USA, Inc. | 18 | $548 |
| E.r. Squibb & Sons, L.L.C. | 10 | $354 |
| Axsome Therapeutics, Inc. | 3 | $250 |
| Lundbeck LLC | 15 | $246 |
| Vanda Pharmaceuticals Inc. | 12 | $218 |
| Corium, LLC | 6 | $171 |
| Avanir Pharmaceuticals, Inc. | 6 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $148 |
| Eisai Inc. | 1 | $107 |
| Indivior Inc. | 6 | $97 |
| Tris Pharma Inc | 1 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$928
- CAPLYTA$702
- INGREZZA$213
- LATUDA$115
- REXULTI$113
- Auvelity$112
- COBENFY$112
- INVEGA SUSTENNA$111
- ABILIFY MAINTENA$109
- ABILIFY ASIMTUFII$109
- Leqembi$107
How this compares
$12,481 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $251,381 |
| Austedo XrDeutetrabenazine | 21 | $208,718 |
| Invega TrinzaPaliperidone Palmitate | 13 | $103,947 |
| Abilify MaintenaAripiprazole | 40 | $98,995 |
| AustedoDeutetrabenazine | 11 | $82,063 |
| Invega SustennaPaliperidone Palmitate | 18 | $61,999 |
| CaplytaLumateperone Tosylate | 30 | $49,218 |
| VraylarCariprazine Hcl | 11 | $13,695 |
| Lurasidone Hcl | 25 | $10,074 |
| Olanzapine | 204 | $7,869 |
| Paliperidone ErPaliperidone | 30 | $3,658 |
| Aripiprazole | 73 | $2,316 |
| Haloperidol Decanoate | 43 | $1,986 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $1,689 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $1,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $548 | $290,78132 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,141 | $251,38131 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $867 | $165,94631 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,396 | $98,99540 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,931 | $49,21830 claims |
| AbbVieVraylar | $852 | $13,69511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Cassopolis
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
- Samuel WedesLivonia$158K
- Arash JavanbakhtDetroit$102K
- Theodore RuzaWest Bloomfield$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.